

USE OF EXOSOMES DERIVED FROM MESENCHYMAL STROMAL CELLS IN THE TREATMENT OF POST-COVID SYNDROME

Post-COVID syndrome is characterized by the presence of fatigue, shortness of breath, changes in smell and taste, chest pain, muscle pain, among other symptoms, that persist for weeks or months after COVID infection.



- During acute infection, the large production of components of the immune system responsible for eradicating the virus can even damage the cells and tissues of the body itself.
- Cell therapy based on Mesenchymal Stromal Cells (MSC) has gained interest in the treatment of both COVID-19 and post-COVID syndrome due to its ability to promote tissue regeneration and regulate the immune response.
- MSCs achieve an anti-inflammatory effect thanks to the exosomes they release, which contain a large number of biochemical molecules with therapeutic actions.

If you were diagnosed with COVID-19 or suffer from Post-COVID Syndrome, at Red Excel we can help you.

Trunk Cell Bank endorsed by COFEPRIS.
Sanitary license 21-TR-02-004-0003